Insmed
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 912
- Market Cap
- $13.2B
- Introduction
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Liposomal amikacin for inhalation
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 206
- Registration Number
- NCT01316276
Study to Evaluate Arikaceâ„¢ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Phase 3
Withdrawn
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Liposomal amikacin for inhalationDrug: Placebo for liposomal amikacin for inhalation
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Insmed Incorporated
- Registration Number
- NCT01315691
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria
Phase 2
Completed
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- Drug: placeboDrug: Liposomal amikacin for inhalation (LAI)
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 90
- Registration Number
- NCT01315236
Study to Evaluate Arikayceâ„¢ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
Phase 3
Completed
- Conditions
- Pseudomonas Aeruginosa Infection
- Interventions
- Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 302
- Registration Number
- NCT01315678
Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACEâ„¢)
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: ARIKACEâ„¢Drug: Placebo
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 66
- Registration Number
- NCT00777296
Safety and Tolerability Study of 2 Dose Level of Arikayceâ„¢ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
Phase 2
Completed
- Conditions
- Bronchiectasis
- Interventions
- Drug: Matching Placebo for Cohort 2Drug: 560 mg Arikayceâ„¢Drug: 280 mg Arikayceâ„¢Drug: Matching Placebo for Cohort 1
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT00775138
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Phase 2
Completed
- Conditions
- Myotonic Dystrophy Type 1
- Interventions
- Drug: placebo
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 69
- Registration Number
- NCT00577577
- Locations
- 🇺🇸
University of Texas Health Science Center, San Antonio, Texas, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇺🇸Ohio State University Medical Center, Columbus, Ohio, United States
Safety/Tolerability Study of Arikayceâ„¢ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Arikayceâ„¢ 70 mgDrug: Placebo for 70 mg / 140 mgDrug: Arikayceâ„¢ 560 mgDrug: Placebo for 560 mgDrug: Arikayceâ„¢ 140 mg
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 41
- Registration Number
- NCT00558844
IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
Phase 2
Completed
- Conditions
- Growth Hormone Insensitivity Syndrome (GHIS)Laron Syndrome
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Insmed Incorporated
- Registration Number
- NCT00368173
- Locations
- 🇮🇹
Maria Carolina Salerno, Naples, Italy
🇧🇷Dr. Durval Damiani, Sao Paulo, Brazil
🇦🇺Dr. Bruce King, Newcastle, Australia
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
Phase 2
Terminated
- Conditions
- Noonan Syndrome
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2007-03-30
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT00351221
- Locations
- 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸Schneider Children's Hospital, New Hyde Park, New York, United States
© Copyright 2025. All Rights Reserved by MedPath